DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

Multiple Sclerosis | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The maturing but highly lucrative market for MS DMTs continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche/Genentech’s Ocrevus has intensified competition in relapsing MS and stokes the perennial debate about early intervention with high efficacy drugs. Meanwhile, the drug is set to meaningfully expand treatment in the underserved progressive MS population. Separately, the looming entry of generic orals threatens to alter payer dynamics in this high-cost market and limit the market potential for follow-on brands as reimbursement authorities race to reign in healthcare costs. Against this complex backdrop, drug developers have resharpened their focus on developing neuroprotective or reparative treatments in MS—now the “next frontier” in a market replete with solid anti-inflammatory options. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.

Questions Answered:

  • What is the commercial outlook for Ocrevus compared with other potent DMTs? What impact will Ocrevus have in the progressive MS market, specifically?
  • How will generic competition shape the MS market, and when will it occur?
  • What clinical roles will entrenched platform injectables, current and next-generation orals, and MAbs play in the evolving MS treatment algorithm?
  • What do KOLs think about Biogen’s potentially ground-breaking remyelinating therapy opicinumab?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • November 2018
      • September 2018
      • June 2018
      • October 2017
      • August 2017
      • June 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Multiple Sclerosis?
        • What Factors Are Constraining the Market for Multiple Sclerosis?
      • Drug-Class-Specific Trends
        • Recombinant IFN-βs
        • Polypeptides
        • Integrin Antagonists
        • S1P Receptor Modulators
        • Pyrimidine Synthesis Inhibitors
        • Nrf2 Pathway Activators
        • Anti-CD52 MAbs
        • Anti-CD20 MAbs
        • Oral Immunosuppressants
    • Forecast
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Overview
      • Natural History
      • Etiology
      • Pathophysiology
      • Key Pathways and Drug Targets
        • Inflammation/Autoimmune Attack
        • Demyelination and Inhibition of Remyelination
        • Neurodegeneration
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Multiple Sclerosis
        • Drug-Treated Cases of Multiple Sclerosis
        • Subpopulations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • IFN-βs
        • Polypeptides
        • Integrin Antagonists
        • Sphingosine-1-Phosphate Receptor Modulators
        • Pyrimidine Synthesis Inhibitors
        • Nrf2 Pathway Activators
        • Anti-CD52 Monoclonal Antibodies
        • Anti-CD20 Monoclonal Antibodies
        • Oral Immunosuppressants
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Risk of PML with MS DMTs
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Multiple Sclerosis
    • Emerging Therapies
      • Key Findings
        • Pipeline Overview
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Multiple Sclerosis
        • Sphingosine-1-Phosphate Receptor Modulators
        • Anti-CD20 Monoclonal Antibodies
        • Tyrosine Kinase Inhibitors
        • Phosphodiesterase Inhibitors
        • Anti-LINGO-1 Monoclonal Antibodies
        • Nrf2 Pathway Activators
        • Vitamins
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Multiple Sclerosis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
      • Bottom-Up Forecasting Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Multiple Sclerosis Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Sarah Soucy; Sunali D. Goonesekera, SM
  • Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism

  • Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group. Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Purchase Report

Recent reports:
You may also be interested in: